344 related articles for article (PubMed ID: 28370444)
21. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
Longhurst HJ; Aberer W; Bouillet L; Caballero T; Maurer M; Fabien V; Zanichelli A;
Eur J Emerg Med; 2016 Jun; 23(3):224-7. PubMed ID: 27116379
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
[TBL] [Abstract][Full Text] [Related]
23. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
[TBL] [Abstract][Full Text] [Related]
24. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
Longhurst HJ; Aberer W; Bouillet L; Caballero T; Fabien V; Zanichelli A; Maurer M;
Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822
[TBL] [Abstract][Full Text] [Related]
25. How satisfactory is on-demand icatibant from the patients' perspective in real life?
Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
[No Abstract] [Full Text] [Related]
26. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
[TBL] [Abstract][Full Text] [Related]
28. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
Piras V; Alves F; Gonçalo M
Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
[TBL] [Abstract][Full Text] [Related]
29. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
30. Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years.
Farkas H; Kőhalmi KV
Expert Rev Clin Immunol; 2018 Jun; 14(6):447-460. PubMed ID: 29757016
[TBL] [Abstract][Full Text] [Related]
31. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
[TBL] [Abstract][Full Text] [Related]
32. Icatibant for the treatment of hereditary angioedema.
Cole SW; Lundquist LM
Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
[TBL] [Abstract][Full Text] [Related]
33. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
34. Icatibant for hereditary angioedema.
Gras J
Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
[TBL] [Abstract][Full Text] [Related]
35. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting.
Zanichelli A; Longhurst HJ; Maurer M; Bouillet L; Aberer W; Fabien V; Andresen I; Caballero T;
Ann Allergy Asthma Immunol; 2016 Oct; 117(4):394-398. PubMed ID: 27742086
[TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
Wang Y; Jomphe C; Marier JF; Martin P
J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
[TBL] [Abstract][Full Text] [Related]
37. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study.
Zanichelli A; Bova M; Coerezza A; Petraroli A; Triggiani M; Cicardi M
Allergy; 2012 Aug; 67(8):1074-7. PubMed ID: 22686628
[TBL] [Abstract][Full Text] [Related]
38. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A
Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
[TBL] [Abstract][Full Text] [Related]
39. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
40. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.
Maurer M; Aberer W; Bouillet L; Caballero T; Fabien V; Kanny G; Kaplan A; Longhurst H; Zanichelli A;
PLoS One; 2013; 8(2):e53773. PubMed ID: 23390491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
